Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 5/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 5/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.45 |
| ▸ | HTR2C | P28335 | 4/20 | 0.45 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.44 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.42 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.42 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.42 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.42 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.42 |
| ▸ | CDK4 | P11802 | 1/20 | 0.39 |
| ▸ | CCND1 | P24385 | 1/20 | 0.39 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4291385 | 1.00 | NFE2L2 (0.57) | NFE2L2PTGS1PTGS2HTR2AKCNH2 | |
| SCHEMBL3720644 | 1.00 | NFE2L2 (0.57) | NFE2L2PTGS1PTGS2HTR2AKCNH2 | |
| SCHEMBL7810204 | 0.92 | NFE2L2 (0.53) | NFE2L2PTGS1PTGS2HTR2AKCNH2 | |
| SCHEMBL7810200 | 0.92 | NFE2L2 (0.53) | NFE2L2PTGS1PTGS2HTR2AKCNH2 | |
| SCHEMBL31182057 | 0.83 | NFE2L2 (0.57) | NFE2L2CDK4CCND1 | |
| SCHEMBL706361 | 0.83 | NFE2L2 (0.57) | NFE2L2CDK4CCND1 | |
| SCHEMBL706360 | 0.83 | NFE2L2 (0.57) | NFE2L2CDK4CCND1 | |
| SCHEMBL12651352 | 0.82 | XDH (0.50) | NFE2L2HTR2AKCNH2HTR2CCYP1A1 | |
| SCHEMBL21676102 | 0.80 | TDP1 (0.44) | NFE2L2CDK4CCND1 | |
| SCHEMBL21631066 | 0.80 | CDK4 (0.37) | NFE2L2CDK4CCND1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12050224-B2 | Compounds useful as near-infrared fluorescent probes selectively binding to tau aggregates and method of preparing the same | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2024-07-30 | — | — | US | disclosed |
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-20210255203-A1 | NOVEL COMPOUNDS USEFUL AS NEAR-INFRARED FLUORESCENT PROBES SELECTIVELY BINDING TO TAU AGGREGATES AND METHOD OF PREPARING THE SAME | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2021-08-19 | — | — | US | disclosed |
| EP-3239139-B1 | CHEMICAL SYNTHESIS AND ANTI-TUMOR AND ANTI-METASTATIC EFFECTS OF DUAL FUNCTIONAL CONJUGATE | NINGBO COMBIREG PHARMACEUTICAL TECH CO LTD (CN) | 2020-10-28 | — | — | EP | disclosed |
| EP-3313837-B1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| US-20200165229-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2020-05-28 | — | — | US | disclosed |
| CN-108341801-B | Polyfluoro-substituted aromatic heterocycle derivatives, pharmaceutical composition containing polyfluoro-substituted aromatic heterocycle derivatives and application of polyfluoro-substituted aromatic heterocycle derivatives | 浙江大学 | 2020-05-12 | — | — | CN | disclosed |
| US-10570129-B2 | Carboline antiparasitics | ZOETIS SERVICES LLC (US) | 2020-02-25 | — | — | US | disclosed |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | ZOETIS SERVICES LLC (US) | 2020-01-30 | — | — | US | disclosed |
| WO-2018137555-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC COMPOUND DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | 浙江大学 | 2018-08-02 | — | — | WO | disclosed |
| US-20110263572-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS | MIMETICA PTY LTD (AU) | 2011-10-27 | — | — | US | disclosed |
| US-8008291-B2 | 3-aminoalkyl-1,4-diazepan-2-one melanocortin-5 receptor antagonists | MIMETICA PTY LTD (AU) | 2011-08-30 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-08 | — | — | US | disclosed |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | Marp Therapeutics Pty Ltd (AU) | 2009-09-03 | — | — | US | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| WO-2007077961-A2 | FUSED HETEROCYCLIC COMPOUNDS AND THEIR USE AS MINERALOCORTICOID RECEPTOR LIGANDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-12 | — | — | WO | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200165229-A1 | POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF | BPHL, AR, FRK | NFE2L2 1363/4885PTGS1 2324/4885PTGS2 2933/4885 |
| US-20110263572-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | NFE2L2 2310/4885PTGS1 983/4885PTGS2 1168/4885 |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | NFE2L2 846/4885PTGS1 3838/4885PTGS2 3418/4885 |
| US-12050224-B2 | Compounds useful as near-infrared fluorescent probes selectively binding to tau aggregates and method of preparing the same | MAPT, PSEN1, PSEN2 | NFE2L2 1758/4885PTGS1 3959/4885PTGS2 4127/4885 |
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | AKT1, AKT2, AKT3 | NFE2L2 1658/4885PTGS1 1766/4885PTGS2 2600/4885 |
| US-20210255203-A1 | NOVEL COMPOUNDS USEFUL AS NEAR-INFRARED FLUORESCENT PROBES SELECTIVELY BINDING TO TAU AGGREGATES AND METHOD OF PREPARING THE SAME | MAPT, PSEN1, PSEN2 | NFE2L2 1882/4885PTGS1 4124/4885PTGS2 4235/4885 |
| US-20090221558-A1 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR | MC5R, MC1R, MC3R | NFE2L2 1613/4885PTGS1 472/4885PTGS2 573/4885 |
| US-20090221557-A1 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS | MC5R, MC1R, MC3R | NFE2L2 2193/4885PTGS1 957/4885PTGS2 1151/4885 |
| US-10570129-B2 | Carboline antiparasitics | ADRA1D, DRD1, CHRM1 | NFE2L2 2540/4885PTGS1 1565/4885PTGS2 1867/4885 |
| US-20090253687-A1 | Fused Heterocyclic Compounds and Their Use as Mineralocorticoid Receptor Ligands | NR3C2, NR3C1, MC2R | NFE2L2 2410/4885PTGS1 437/4885PTGS2 697/4885 |
| US-20200031822-A1 | CARBOLINE ANTIPARASITICS | DRD1, ADRA1D, DRD2 | NFE2L2 2483/4885PTGS1 1431/4885PTGS2 2031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.